News >

Apalutamide Improves Survival in Metastatic Castration-Sensitive Prostate Cancer

Gina Columbus @ginacolumbusonc
Published: Wednesday, Jan 30, 2019

Prostate Cancer
Apalutamide (Erleada) in combination with androgen deprivation therapy (ADT) was found to significantly improve radiographic progression-free survival (rPFS) and overall survival (OS) versus placebo in patients with metastatic castration-sensitive prostate cancer, according to topline findings of the phase III TITAN trial (NCT02489318).1

 

References

  1. Janssen Announces ERLEADA®(apalutamide) Phase 3 TITAN Study Unblinded as Dual Primary Endpoints Achieved in Clinical Program Evaluating Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer. Janssen. Published January 30, 2019. https://bit.ly/2UuyCL1. Accessed January 30, 2019.
  2. Small EJ, Saad F, Chowdhury S et al. SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). J Clin Oncol. 2018;36(suppl 6s; abstract 161).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x